These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1027 related items for PubMed ID: 17938629

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Management of visceral leishmaniasis: Indian perspective.
    Agrawal S, Rai M, Sundar S.
    J Postgrad Med; 2005; 51 Suppl 1():S53-7. PubMed ID: 16519257
    [Abstract] [Full Text] [Related]

  • 6. Leishmaniasis: an update of current pharmacotherapy.
    Sundar S, Chakravarty J.
    Expert Opin Pharmacother; 2013 Jan; 14(1):53-63. PubMed ID: 23256501
    [Abstract] [Full Text] [Related]

  • 7. Visceral leishmaniasis.
    van Griensven J, Diro E.
    Infect Dis Clin North Am; 2012 Jun; 26(2):309-22. PubMed ID: 22632641
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
    Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, Figueras C, Gradoni L, Kafetzis DA, Ritmeijer K, Rosenthal E, Royce C, Russo R, Sundar S, Alvar J.
    Clin Infect Dis; 2006 Oct 01; 43(7):917-24. PubMed ID: 16941377
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Treatment options for visceral leishmaniasis.
    den Boer M, Davidson RN.
    Expert Rev Anti Infect Ther; 2006 Apr 01; 4(2):187-97. PubMed ID: 16597201
    [Abstract] [Full Text] [Related]

  • 13. The treatment of visceral leishmaniasis: safety and efficacy.
    Jha RK, Sah AK, Shah DK, Sah P.
    JNMA J Nepal Med Assoc; 2013 Apr 01; 52(192):645-51. PubMed ID: 25327244
    [Abstract] [Full Text] [Related]

  • 14. Chemotherapeutics of visceral leishmaniasis: present and future developments.
    Sundar S, Singh A.
    Parasitology; 2018 Apr 01; 145(4):481-489. PubMed ID: 29215329
    [Abstract] [Full Text] [Related]

  • 15. Paromomycin.
    Davidson RN, den Boer M, Ritmeijer K.
    Trans R Soc Trop Med Hyg; 2009 Jul 01; 103(7):653-60. PubMed ID: 18947845
    [Abstract] [Full Text] [Related]

  • 16. Visceral leishmaniasis in children: a review.
    Palumbo E.
    Minerva Pediatr; 2010 Aug 01; 62(4):389-95. PubMed ID: 20940672
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum.
    Lachaud L, Bourgeois N, Plourde M, Leprohon P, Bastien P, Ouellette M.
    Clin Infect Dis; 2009 Jan 15; 48(2):e16-22. PubMed ID: 19093811
    [Abstract] [Full Text] [Related]

  • 19. Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator-Picroliv.
    Shakya N, Sane SA, Vishwakarma P, Bajpai P, Gupta S.
    Acta Trop; 2011 Aug 15; 119(2-3):188-93. PubMed ID: 21679679
    [Abstract] [Full Text] [Related]

  • 20. Visceral leishmaniasis (kala-azar): challenges ahead.
    Singh RK, Pandey HP, Sundar S.
    Indian J Med Res; 2006 Mar 15; 123(3):331-44. PubMed ID: 16778314
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.